What are the best strategies for headache and migraine prevention?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Best Strategies for Headache and Migraine Prevention

First-line pharmacologic treatments for migraine prevention include β-blockers (propranolol, timolol), antiseizure medications (valproate), tricyclic antidepressants (amitriptyline), and SNRIs (venlafaxine), which should be tried before newer, more expensive options like CGRP antagonists or monoclonal antibodies. 1, 2

Pharmacologic Prevention Strategies

When to Consider Preventive Therapy

  • Initiate preventive therapy when patients experience two or more migraine attacks per month with disability lasting 3+ days per month 1, 2
  • Consider prevention when patients use acute medications more than twice per week 1
  • Evaluate for prevention when patients have contraindications to or failure of acute treatments 1
  • Prevention is indicated for uncommon migraine conditions, including hemiplegic migraine or migraine with prolonged aura 1

First-Line Pharmacologic Options

  • β-blockers: propranolol (80-240 mg/day) and timolol (20-30 mg/day) have established efficacy with Level A evidence 1, 3
  • Antiseizure medications: divalproex sodium (500-1500 mg/day) and sodium valproate (800-1500 mg/day) are effective first-line options 1, 2
  • Tricyclic antidepressants: amitriptyline (30-150 mg/day) has consistent evidence supporting efficacy 1, 2
  • SNRIs: venlafaxine is recommended as a first-line option by current guidelines 1, 2

Second-Line Pharmacologic Options

  • Topiramate: suggested after failure of first-line agents due to higher frequency of adverse events 1
  • CGRP antagonists-gepants (atogepant, rimegepant) or CGRP-mAbs (eptinezumab, erenumab, fremanezumab, galcanezumab): consider after failure of first-line agents due to substantially higher costs 1
  • ACE inhibitors (lisinopril) or ARBs (candesartan, telmisartan): consider if recommended treatments are not tolerated or result in inadequate response 1

Non-Pharmacologic Prevention Strategies

Lifestyle Modifications

  • Identify and manage modifiable triggers through headache diaries 1, 2, 4
  • Maintain regular sleep patterns and adequate hydration 1, 2
  • Engage in regular physical activity - aerobic exercise 2-3 times weekly for 30-60 minutes is effective for prevention 1
  • Implement stress management techniques 2, 4

Behavioral Interventions

  • Cognitive behavioral therapy has demonstrated efficacy for migraine prevention 1, 2, 5
  • Biofeedback and relaxation training are effective non-pharmacologic approaches 1, 5
  • Progressive muscle relaxation techniques can help reduce headache frequency 1, 5

Physical Therapy

  • Physical therapy including thermal methods, trigger point massage, and mobilization techniques can be beneficial for migraine and tension-type headache management 1
  • Progressive strength training, particularly upper-body exercises, can help prevent both migraine and tension-type headaches 1

Implementation Best Practices

Medication Administration

  • Start preventive medications at a low dose and gradually titrate up to minimize side effects 1, 2
  • Allow adequate trial periods (2-3 months) before determining effectiveness 1
  • Monitor for adverse effects and adjust accordingly 1

Patient Education and Monitoring

  • Use headache diaries to track frequency, severity, duration, and response to treatment 1, 2
  • Educate patients that migraine is a neurological disorder with a biological basis 1
  • Set realistic expectations that improvement may occur gradually after initiation of preventive treatment 1

Common Pitfalls to Avoid

  • Discontinuing treatment too early before therapeutic effect is achieved (typically needs 2-3 months) 1, 2
  • Not starting at low doses and gradually titrating up, leading to unnecessary side effects 1, 2
  • Failing to address medication overuse, which can lead to rebound headaches 2, 6
  • Overlooking comorbid conditions that may influence treatment selection 1, 2

Special Populations

  • In women of childbearing potential, discuss potential teratogenic effects, particularly with valproate and topiramate 1, 2
  • Consider pregnancy and breastfeeding status when selecting preventive medications 1

By following these evidence-based strategies and selecting appropriate preventive treatments based on individual factors, migraine frequency and severity can be significantly reduced, improving quality of life and reducing disability.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Migraine Prevention and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.